Abionyx : A new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. ABIONYX plans to explore joint activities with attractive partners.
Location: France, Occitania, Balma
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | TVM Capita... | tvm-lifesc... |
Mentions in press and media 4
| Date | Title | Description |
| 17.11.2021 | ABIONYX Pharma : announces the signing of an agreement for the contribution of 100% of the capital of IRIS Pharma Holding, fully remunerated by the issuance of new shares at a fixed price of 3.60 euro... | Press release ABIONYX announces the signing of an agreement for the contribution of 100% of the capital of IRIS Pharma Holding, fully remunerated by the issuance of new ABIONYX shares at a fixed price of 3.60 euros per share ABIONYX announc... |
| 16.06.2021 | ABIONYX PHARMA ABIONYX Pharma : presents its “raison d'être” and states in its articles of association | Press release ABIONYX Pharma presents its "raison d'être" and states in its articles of association: "To develop innovative therapies in indications without effective or existing treatment, even the rarest ones, for the benef... |
| 27.04.2021 | ABIONYX PHARMA SA Abionyx Pharma : Availability of the Universal Registration Document for the year 2020 | Press Release Availability of the Universal Registration Document for the year 2020 Produced in the European Single Electronic Format "European Single Electronic Format" (ESEF), facilitating comparability and access to financial i... |
| 02.03.2021 | Abionyx Pharma : Positive Clinical Results From CER-001 in an ultrarare kidney disease Published in The Annals of Internal Medicine | Press release ABIONYX Announces Positive Clinical Results From CER-001 in an ultrarare kidney disease Published in The Annals of Internal Medicine • Demonstrated efficacy in renal and ophthalmic indication • Confirmation of the breakthrough... |